More than 47,000 women underwent individualized, no-obligation risk assessment to determine their risk of breast cancer and weigh the pros and cons of joining the trial. We hope to reach our goal earlier, within the next few years. Raloxifene was shown to reduce the incidence of breast cancer in a large osteoporosis trial. In ongoing studies, raloxifene has not been associated with increased endometrial cancer risk. STAR will help further define the risks and benefits of tamoxifen and raloxifene therapy.
Financial aid is available to women who qualify to fulfill study requirements.
Once a woman decides to participate, she is randomly assigned to receive either 20 mg tamoxifen or 60 mg raloxifene daily for five years. Every woman receives regular follow-up examinations.